There is a problem hiding in plain sight inside every pharmacy in India. When a chemist in Pune needs to reorder antibiotics, the process looks like this. A distributor’s salesman arrives. An order is written on paper or WhatsApp. Payment happens days or weeks later in cash. Credit is informal. Reconciliation is manual. The same workflow repeats across 6.5 lakh pharmacies and 65,000 distributors across India every single day.
That workflow is why India’s Rs 2.5 lakh crore pharmaceutical distribution market is one of the most fragmented and operationally inefficient sectors in the country. And it is the exact problem that Fundly.ai was built to solve. Stay ahead of every India startup funding story at BestStartup India.
Fundly.ai Raises $4 Million Pre-Series A — The Round That Matters
On September 8 2026, Fundly.ai announced it has raised $4 million in a pre-Series A round co-led by existing investors Accel and Multiply Ventures, with participation from Rajeev Ahuja — former executive director at RBL Bank — and other angel investors. The company also raised $900,000 in venture debt from Alteria Capital, taking total fresh capital to approximately $4.9 million and total funding to over $7 million.
Fundly.ai was founded by Amit Chawla in Mumbai in 2021. The company builds an AI-native B2B distribution network for India’s pharmaceutical market — a single platform connecting ordering, payments, settlement, and embedded credit for the secondary pharma trade. The platform currently serves more than 4,100 retailers across 24 cities and more than 600 pin codes. Its Pune pilot covers approximately 3,000 retailers.
Why Accel and Multiply Backed Fundly.ai Again in September 2026
The September 2026 pre-Series A is not Accel and Multiply’s first bet on Fundly.ai. Both firms led the company’s $3 million seed round in 2023. Their decision to re-invest and lead the round again signals confidence in what the company has built. For Accel, the investment fits a pattern of backing B2B fintech infrastructure plays in India where large fragmented markets are underserved by legacy distribution and payment systems.
Rajeev Ahuja’s participation as an angel investor adds specific expertise in credit and banking infrastructure directly relevant to the working capital and embedded credit products Fundly.ai is building. Alteria Capital’s venture debt component gives the company non-dilutive capital to fund working capital operations without further equity dilution. Read more India pharma and B2B startup stories at BestStartup India.
PM Modi’s Rs 1 Lakh Crore Innovation Fund — The Government Backdrop
Fundly.ai’s September 8 raise arrived in the context of one of the most significant government announcements in Indian startup history. On August 15 2026, Prime Minister Narendra Modi used his Independence Day address from the Red Fort to announce a Rs 1 lakh crore innovation fund to support young entrepreneurs and help them turn ideas into businesses.
The announcement was aimed specifically at the next phase of Indian startups — deep technology, manufacturing, AI, clean energy, semiconductors, biotech, space, and advanced research. The government has also notified the Startup India Fund of Funds 2.0 with a Rs 10,000 crore corpus through SIDBI. For B2B infrastructure startups like Fundly.ai operating in the pharmaceutical supply chain, this policy environment creates a backdrop of capital availability and government support that did not exist in previous funding cycles.
India’s Pharma B2B Market — Why September 2026 Is the Right Moment
India’s pharmaceutical market is the world’s largest by volume and third largest by value, projected to reach $65 billion by 2030. The Rs 2.5 lakh crore secondary pharma trade operates primarily on paper, phone calls, and informal credit. Digital adoption among pharma distributors and retailers is still in early stages. Payment cycles are long. Credit is expensive or unavailable to smaller retailers.
This creates exactly the conditions where a well-designed B2B commerce and fintech platform can create substantial value. Fundly.ai does not need to change how pharma distribution works. It needs to make what already happens work better — a significantly lower adoption barrier than asking distributors and retailers to adopt entirely new business models.
Top 10 India Pharma and B2B Startups to Watch in 2026
The Fundly.ai raise is the latest signal that India’s B2B and pharma tech ecosystem is entering a new phase. Here are 10 companies defining this moment in India’s pharma and health B2B space:
- Fundly.ai — AI-native pharma B2B distribution, payments and embedded credit — Mumbai — $7M+ total raised
- Aknamed — Medical supply chain procurement for hospitals — Bengaluru — Series B
- Pharmarack — B2B pharma ordering and distribution platform — Pune — Series B
- Retailio — Pharma B2B marketplace connecting distributors and retailers — Mumbai — Sequoia backed
- Zeelab Pharmacy — Affordable generic medicine retail franchise — Pan-India
- Medikabazaar — Hospital supply procurement marketplace — Mumbai — Series C
- 1mg — Online pharmacy and health platform — Gurugram — Tata-owned
- PharmEasy — Online pharmacy and B2B supply — Mumbai — Listed
- Netmeds — Online pharmacy platform — Chennai — Reliance-owned
- Medibuddy — Digital health and corporate wellness — Bengaluru — Series C
Fundly.ai Key Takeaways
Fundly.ai raised $4 million pre-Series A on September 8 2026 co-led by Accel and Multiply Ventures. Total funding including $900,000 venture debt is approximately $4.9 million. Total funding since founding is over $7 million. The Mumbai company serves 4,100 plus retailers across 24 cities and 600 plus pin codes. Founder Amit Chawla built the platform to connect ordering, payments, settlement, and embedded credit for India’s Rs 2.5 lakh crore pharma distribution market. PM Modi announced a Rs 1 lakh crore innovation fund on August 15 2026. The Startup India Fund of Funds 2.0 has a Rs 10,000 crore corpus managed through SIDBI. India’s pharmaceutical market is projected to reach $65 billion by 2030. Follow every India startup story at BestStartup India.
Frequently Asked Questions
What is Fundly.ai and what does it do?
Fundly.ai is a Mumbai-based B2B pharma distribution startup founded by Amit Chawla in 2021. It builds an AI-native platform connecting ordering, payments, settlement, and embedded credit for India’s pharmaceutical secondary trade — the relationship between manufacturers, distributors, and 6.5 lakh retail pharmacies.
How much did Fundly.ai raise on September 8 2026?
Fundly.ai raised $4 million pre-Series A co-led by Accel and Multiply Ventures plus $900,000 venture debt from Alteria Capital, taking total fresh capital to approximately $4.9 million and total funding to over $7 million.
What is PM Modi’s Rs 1 lakh crore innovation fund?
PM Modi announced a Rs 1 lakh crore innovation mechanism on August 15 2026 to support young entrepreneurs in deep tech, manufacturing, AI, clean energy, semiconductors, biotech, and space. It is linked to India’s Research, Development, and Innovation Fund over six years.
What is the Startup India Fund of Funds 2.0?
The Startup India Fund of Funds 2.0 is a Rs 10,000 crore government scheme notified in April 2026 to mobilise venture and growth capital for Indian startups in deep tech, early growth-stage, and innovative manufacturing, managed through SIDBI and SEBI-registered AIFs.
Where can I follow India startup funding news?
Follow every India startup funding round, company profile, and ecosystem story at BestStartup India — updated every week.
